Search results for "ALPHA"

showing 10 items of 3228 documents

2',5'-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papil…

2004

Objective: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course,as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis. Methods: Forty-two patients with recurrent respiratory papillomatosis were treated with interferon-alpha (3 MU/m2 three times per week; mean therapy duration was 2.7 ± 1.8 years)in 1983–1994 and followed-up until 2003. Human papilloma virus (HPV) type, recurrent respiratory papillomatosis severity and 2′,5′-oligo…

AdultMalemedicine.medical_specialtyAdolescent2'-5'-oligoadenylate synthetase activityAntineoplastic AgentsGastroenterologySeverity of Illness IndexVirusMalignant transformationBasal (phylogenetics)Internal medicinemedicine2'5'-Oligoadenylate SynthetaseHumansTypingProspective StudiesChildPapillomaviridaePapillomabusiness.industryInterferon-alphaGeneral Medicinemedicine.diseasePrognosisRespiratory Tract NeoplasmsTreatment OutcomeOtorhinolaryngologyChild PreschoolImmunologyDNA ViralLeukocytes MononuclearPapillomaFemaleRecurrent Respiratory PapillomatosisNeoplasm Recurrence LocalAirwaybusinessThe Journal of laryngology and otology
researchProduct

Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-up

2005

Objectives: The aim of this study was analysis of the results of use of interferon-α (IFN-α) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type. Methods: A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-α in doses of 3 MU/m2 3 times per week. Results: During long-term follow-up (mean ± SD, 172 ± 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease cour…

AdultMalemedicine.medical_specialtyAdolescentAlpha interferonAntineoplastic AgentsInjections IntramuscularDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapyHumansDNA Probes HPVProspective StudiesHuman papillomavirusChild030223 otorhinolaryngologyProspective cohort studyLaryngeal NeoplasmsPapillomaviridaeInterferon alfaPapillomabusiness.industryIncidence (epidemiology)InfantInterferon-alphaGeneral MedicineMiddle AgedSurgeryClinical trialTreatment OutcomeOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRecurrent Respiratory PapillomatosisbusinessFollow-Up Studiesmedicine.drugAnnals of Otology, Rhinology & Laryngology
researchProduct

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard…

2011

Abstract The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then…

AdultMalemedicine.medical_specialtyAdolescentCyclophosphamideImmunologyAzathioprineBehcet's diseaseRheumatologyPrednisoneInternal medicinemedicineHumansImmunology and AllergyAdverse effectAgedTumor Necrosis Factor-alphabusiness.industryBehcet SyndromeAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabSurgeryDiscontinuationBehçet’s disease - TNF alfa - InfliximabClinical trialTreatment OutcomeAntirheumatic AgentsFemalebusinessmedicine.drug
researchProduct

Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with imm…

2013

The objective of this study was to analyze the accuracy of abdominal ultrasonography (AUS) in the assessment of mucosal healing in patients with Crohn's disease (CD) receiving immunomodulators and/or biological treatment, with ileocolonoscopy as the reference standard.Thirty patients were included in a prospective longitudinal study. All patients underwent ileocolonoscopy and AUS before and after a minimum of one year of treatment. The Crohn's Disease Endoscopic Inflammatory Index of Severity (CDEIS) was used for endoscopic assessment whereas AUS was analyzed by means of bowel wall thickness, color Doppler grade and percentage of increase of parietal enhancement after contrast injection.In …

AdultMalemedicine.medical_specialtyAdolescentDoppler echocardiographySeverity of Illness IndexEndoscopy GastrointestinalYoung AdultIntestinal mucosaAdjuvants ImmunologicCrohn DiseaseMedicineHumansImmunologic FactorsProspective StudiesBiological response modifiersIntestinal MucosaUltrasonography Doppler ColorCrohn's diseasemedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaGastroenterologyMucous membraneMagnetic resonance imagingGeneral Medicinemedicine.diseaseEndoscopymedicine.anatomical_structureAbdominal ultrasonographyFemaleRadiologybusinessFollow-Up StudiesJournal of Crohn'scolitis
researchProduct

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level

2014

Patients with diabetes caused by single-gene mutations generally exhibit an altered course of diabetes. Those with mutations of the glucokinase gene (GCK-MODY) show good metabolic control and low risk of cardiovascular complications despite paradoxically lowered high-density lipoprotein (HDL) cholesterol levels. In order to investigate the matter, we analyzed the composition of low-density lipoprotein (LDL) and HDL subpopulations in such individuals. The LipoPrint(©) system (Quantimetrix, USA) based on non-denaturing, linear polyacrylamide gel electrophoresis was used to separate and measure LDL and HDL subclasses in fresh-frozen serum samples from patients with mutations of glucokinase or …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismBiologyLipid subpopulationsYoung Adultchemistry.chemical_compoundEndocrinologyMonogenic diabetesInternal medicineDiabetes mellitusGlucokinasemedicineInternal MedicineHumansHepatocyte Nuclear Factor 1-alphaChildType 1 diabetesmedicine.diagnostic_testCholesterolGlucokinaseCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseLipoproteins LDLDiabetes Mellitus Type 1EndocrinologychemistryCase-Control StudiesMetabolic control analysisMODYOriginal ArticleFemalelipids (amino acids peptides and proteins)Lipoproteins HDLLipid profileLipoproteinActa Diabetologica
researchProduct

Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men

2013

Metabolic syndrome (MetS) is associated with increased oxidized LDL (ox-LDL), systemic inflammation, and poor cardiorespiratory fitness. We examined affiliations of these factors and the effect of muscular fitness on MetS in young healthy men.Physical fitness, ox-LDL, tumor necrosis factor α (TNFα), interleukin-6 (IL-6) and serum lipids were measured in a nationally representative sample of Finnish young men with and without MetS. Participants (mean age 25.1years) performed tests of maximal oxygen uptake (VO₂max) and muscle fitness, and were divided into MetS (n=54, IDF 2007 criteria) and non-MetS (n=790). Age, smoking and leisure-time physical activity were used as covariates (ANCOVA).The …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismPhysical fitnessBlood lipidsBiologyta3111Young AdultGrip strengthOxygen ConsumptionEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansYoung adultta315FinlandAbdominal MusclesMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphabusiness.industryMyocardiumVO2 maxHeartCardiorespiratory fitnessMiddle Agedmedicine.diseaseRespiratory MusclesLipoproteins LDLCross-Sectional StudiesEndocrinologyPhysical FitnessMetabolic syndromebusinessBody mass indexMetabolism
researchProduct

Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients’ and doctors’ views

2011

Treatment of malignant melanoma with IFN-α has been associated with significant side-effects. The aim of this retrospective monocentric non-randomized study was first to evaluate the impact on quality of life (QOL) in 30 melanoma patients treated with once weekly 2 μg/kg PEG-IFN-α2b for 18 months, and second to examine whether there is a difference in patients' and physicians' perception of QOL. Data on QOL were collected by means of the EORTC QLQ-C30 questionnaire completed by the patient before consultation at baseline and every three months during treatment. A second questionnaire was filled out independently by the physician, based on the consultation and patient file. All data were rou…

AdultMalemedicine.medical_specialtyAdolescentEvery Three Monthsmedicine.medical_treatmentOnce weeklyDermatologyInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultAmbulatory careQuality of lifePegylated interferonHumansMedicineIn patientMelanomaAgedRetrospective StudiesAged 80 and overbusiness.industryMelanomaInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinshumanitiesChemotherapy AdjuvantQuality of LifePhysical therapyFemalebusinessAdjuvantmedicine.drugEuropean Journal of Dermatology
researchProduct

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

2010

The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established.Four hundred and fourteen patients received Peg-interferon alpha-2b plus 1000-1200 mg of ribavirin daily according with body weightor75 kg. Patients were randomized to standard 24 weeks (Std24) or to a 12 or 36 weeks variable treatment duration (Var12/36). In the variable treatment arm, patients with or without wk4-R were allocated to either 12 or 36 weeks duration.At treatment week 4, HCV RNA was undetectable in 262 patients (63.3%), 136 in the Std24, and 126 in the Var12/36 group (p=0.41). In patients with wk4-R, end-of-treat…

AdultMalemedicine.medical_specialtyAdolescentGenotypeAlpha (ethology)Alpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundYoung AdultPharmacotherapyInternal medicineGenotypeRibavirinmedicineHumansIn patientPrecision MedicineAgedHepatologybusiness.industryStomachRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgerymedicine.anatomical_structurechemistryRNA ViralFemalebusinessJournal of hepatology
researchProduct

Development and construct validation of the angioedema quality of life questionnaire

2012

Background Recurrent angioedema is a frequent clinical problem characterized by unpredictably and rapidly occurring cutaneous and mucosal swellings. These swellings may be painful and/or disfiguring. Upper airway involvement can also lead to dyspnea and suffocation. Although the disease burden is high, there is currently no specific instrument to measure health-related quality of life (QoL) impairment. Objective To develop and validate the first symptom-specific tool to assess QoL impairment in recurrent angioedema patients, adhering to established methodological recommendations. Methods During the development phase, 29 questions (items) were generated. Subsequently, item reduction was perf…

AdultMalemedicine.medical_specialtyAdolescentImmunologySeverity of Illness IndexYoung AdultQuality of lifeCronbach's alphaSurveys and QuestionnairesSeverity of illnessmedicineHumansImmunology and AllergyAngioedemaDisease burdenAgedFace validityAged 80 and overAngioedemabusiness.industryReproducibility of ResultsConstruct validityMiddle AgedhumanitiesMoodQuality of LifePhysical therapyFemalemedicine.symptombusinessAllergy
researchProduct

Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry dis…

2008

Fabry disease is an X-chromosomal storage disorder due to loss-of-function mutations of the GLA gene encoding the lysosomal enzyme α-galactosidase A. Accumulating glycosphingolipid deposits disturb the function of various cells, in particular that of myocytes, arterial smooth-muscle cells, and vascular endothelium. Hypertrophic cardiomyopathy, for example measured by left posterior wall thickness (LPWT) of the heart, represents a major component of Fabry disease morbidity in adult patients. Endothelium-derived nitric oxide (eNO), produced by eNO synthase (eNOS), is a key regulator of vessel wall function and cardiovascular homeostasis. We analysed the effect of the polymorphisms c.894G > T …

AdultMalemedicine.medical_specialtyAdolescentNitric Oxide Synthase Type IIIMutation MissenseMinisatellite RepeatsYoung AdultSex FactorsGene FrequencyInternal medicineGermanyGenotypeGeneticsMedicineHumansGenetic Predisposition to DiseaseAlleleChildAllele frequencyGenetics (clinical)AgedUltrasonographyGeneticsAlpha-galactosidasePolymorphism Geneticbiologybusiness.industryMyocardiumHaplotypeHypertrophic cardiomyopathyNitric Oxide Synthase Type IIIExonsCardiomyopathy HypertrophicMiddle Agedmedicine.diseaseFabry diseaseIntronsEndocrinologyPhenotypeHaplotypesCase-Control Studiesalpha-Galactosidasebiology.proteinFabry DiseaseRegression AnalysisFemaleHypertrophy Left VentricularbusinessJournal of inherited metabolic disease
researchProduct